Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals for $10B

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, or $85 per share, a 102% premium to Crinetics' prior closing price . The transaction is Vertex's largest acquisition ever, surpassing its $4.9 billion purchase of Alpine Immune Sciences in 2024, and is expected to close in the third quarter of 2026 pending regulatory approval.

The deal gives VRTX control of CRNX's commercial endocrinology franchise, anchored by Palsonify, an FDA-approved treatment for acromegaly launched last year, and atumelnant, a late-stage Phase 3 candidate for congenital adrenal hyperplasia with multi-billion dollar sales potential . Vertex says the acquisition should become accretive to adjusted operating income in 2029, positioning the combined pipeline to extend beyond its core cystic fibrosis and pain franchises into rare endocrine disease.

News of the acquisition sent Crinetics shares soaring, with the stock nearly doubling toward the $85 offer price after the announcement and ranking among the market's biggest gainers. The move lifted sentiment across healthcare and biotech names more broadly, contributing to the sector's upward momentum for the session. Vertex shares, by contrast, showed a more muted reaction, typical for an acquirer funding a large all-cash deal.

Analysts are split on whether the premium is justified: some argue the price reflects confidence in Palsonify's and atumelnant's blockbuster potential, while others flag integration risk and the concentration of value in a small number of late-stage assets . Investors will be watching regulatory clearance timelines, the pace of atumelnant's path toward approval, and how quickly Vertex can integrate Crinetics' commercial infrastructure as the deal moves toward closing.

Related Stocks

• CRNX
• VRTX